Ben Graham prefers companies' interest coverage to be at least 5. Egyptian International Pharmaceutical Investments interest coverage is 2.25, which is low.
Egyptian International Pharmaceutical Investments (CAI:PHAR) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Egyptian International Pharmaceutical Investments Interest Coverage Related Terms
Egyptian International Pharmaceutical Investments Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Egyptian International Pharmaceutical Investments Interest Coverage Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Interest Coverage vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Interest Coverage of 2.47 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 33% below median its historical median of 3.66. Over the past decade, Egyptian International Pharmaceutical Investments' Interest Coverage has ranged from 1.71 to 6.06. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #575 out of 686 companies in the Drug Manufacturers industry, placing it in the top 83.8%.
Is Egyptian International Pharmaceutical Investments' Interest Coverage too high?
Egyptian International Pharmaceutical Investments' current Interest Coverage of 2.47 is 33% below median its 10-year median of 3.66. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 6.06. The Drug Manufacturers industry median Interest Coverage is 12.73. Egyptian International Pharmaceutical Investments' value of 2.47 is 80.6% below this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #575 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #575 out of 686 companies for Interest Coverage. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median Interest Coverage is 12.73. Egyptian International Pharmaceutical Investments' value of 2.47 is 80.6% below this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Interest Coverage has ranged from 1.71 to 6.06 over the past decade. While the company's 10-year median is 3.66 vs. the industry median of 12.73, Egyptian International Pharmaceutical Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Interest Coverage of 2.47 is 80.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Interest Coverage is 2.47, which is 33% below median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.72, compared to a current price of E£88.21 — trading 47.7% above its estimated fair value. The current Interest Coverage is 2.47, which is 33% below median its 10-year median of 3.66 and 80.6% below the Drug Manufacturers industry median of 12.73. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Interest Coverage is 2.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£88.21 is trading 47.7% above its estimated GF Value™ of E£59.72.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Interest Coverage: 2.47 (33% below median its 10-year median of 3.66)
GF Value™: E£59.72 vs. price of E£88.21 (47.7% above fair value)
Industry Position: 80.6% below the Drug Manufacturers median (#575 of 686)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score
Get the complete analysis for CAI:PHAR
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
